Matches in Nanopublications for { ?s ?p "[The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 14 of
14
with 100 items per page.
- NP167602.RA-MSm1DNtUFFP35Bc2i5y2lc3ypBma3LdrmtVGKesMYw130_assertion description "[The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP167602.RA-MSm1DNtUFFP35Bc2i5y2lc3ypBma3LdrmtVGKesMYw130_provenance.
- NP151431.RAzO9V5Brl5uPEj4z_nGy1JB9liP2mv6fBbn_09vLtjGk130_assertion description "[The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP151431.RAzO9V5Brl5uPEj4z_nGy1JB9liP2mv6fBbn_09vLtjGk130_provenance.
- NP806020.RA_lXB9PZ-TLxWgHQxCpwf56oFo1B2WSvMYZw1k5NKdew130_assertion description "[The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP806020.RA_lXB9PZ-TLxWgHQxCpwf56oFo1B2WSvMYZw1k5NKdew130_provenance.
- NP806007.RAfNla_tlFIU9KYGw-BUfEvKp0R_Lrl8qolJQUd5ScTw8130_assertion description "[The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP806007.RAfNla_tlFIU9KYGw-BUfEvKp0R_Lrl8qolJQUd5ScTw8130_provenance.
- NP647406.RA8gdhRwkUBJlBQ0NjdppyO3FJVZ3x82V26DlIlrFglLk130_assertion description "[The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP647406.RA8gdhRwkUBJlBQ0NjdppyO3FJVZ3x82V26DlIlrFglLk130_provenance.
- NP647407.RA9R7l3twUb4bwJxPf9zlKK7wSi7OyrX1G31OIkVwVPFQ130_assertion description "[The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP647407.RA9R7l3twUb4bwJxPf9zlKK7wSi7OyrX1G31OIkVwVPFQ130_provenance.
- NP647408.RA5eZMvmxfk2789mZAp7aE3Q8zYAz1i0yspPbskzmh0wQ130_assertion description "[The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP647408.RA5eZMvmxfk2789mZAp7aE3Q8zYAz1i0yspPbskzmh0wQ130_provenance.
- NP806073.RAFU3ykZ4Y-ZoVHe-Yy6f8oNLBFNzKOp9txG5GVZiwzSE130_assertion description "[The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP806073.RAFU3ykZ4Y-ZoVHe-Yy6f8oNLBFNzKOp9txG5GVZiwzSE130_provenance.
- assertion description "[The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP805977.RAijRSesfv9T0_qqNrxyGj9nWZO3JU7HDFYD_0bLAnXZ8130_assertion description "[The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP805977.RAijRSesfv9T0_qqNrxyGj9nWZO3JU7HDFYD_0bLAnXZ8130_provenance.
- NP116937.RAEBM6RvJaqXQA1p-52i9agwhLOboTOplY5TLBpW-igok130_assertion description "[The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP116937.RAEBM6RvJaqXQA1p-52i9agwhLOboTOplY5TLBpW-igok130_provenance.